RecruitingPhase 2NCT04644289
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Studying Malignant non-epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AGO Research GmbH
- Principal Investigator
- Frederik Marmé, MDUniversitätsklinikum Mannheim, Frauenklinik
- Intervention
- olaparib(drug)
- Enrollment
- 60 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2028
Study locations (6)
- Universitätsklinikum Mannheim GmbH, Frauenklinik, Mannheim, Baden-Wurttemberg, Germany
- Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde, München, Bavaria, Germany
- Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg, Hamburg, Hamburg, Germany
- KEM Essen | Evang. Kliniken Essen Mitte, Essen, North Rine-Westphalia, Germany
- Universitätsklinikum Carl Gustav Carus Dresden an der technischen Universität Dresden, Gynäkologisches Krebszentrum und Regionales Brustzentrum Dresden am Universitäts-KrebsCentrum, Dresden, Saxony, Germany
- Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, State of Berlin, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04644289 on ClinicalTrials.govOther trials for Malignant non-epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07189871177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRadiopharm Theranostics, Ltd
- RECRUITINGPHASE1NCT07216105FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsFate Therapeutics
- RECRUITINGPHASE1NCT06238479A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsEli Lilly and Company
- ACTIVE NOT RECRUITINGPHASE2NCT06169124Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05872204Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian CancerUniversitaire Ziekenhuizen KU Leuven
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04180371Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionBicycleTx Limited
See all trials for Malignant non-epithelial tumor of ovary →